Logo image of LIMN

LIMINATUS PHARMA INC-CL A (LIMN) Stock Fundamental Analysis

NASDAQ:LIMN - Nasdaq - Common Stock - Currency: USD

6.69  -1.39 (-17.2%)

Premarket: 6.9 +0.21 (+3.14%)

Fundamental Rating

0

Overall LIMN gets a fundamental rating of 0 out of 10. We evaluated LIMN against 553 industry peers in the Biotechnology industry. LIMN has a bad profitability rating. Also its financial health evaluation is rather negative. LIMN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

LIMN had negative earnings in the past year.
In the past year LIMN has reported a negative cash flow from operations.
LIMN Yearly Net Income VS EBIT VS OCF VS FCFLIMN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 0 2M -2M 4M 6M 8M 10M

1.2 Ratios

The Return On Assets of LIMN (-82.22%) is worse than 71.07% of its industry peers.
Industry RankSector Rank
ROA -82.22%
ROE N/A
ROIC N/A
ROA(3y)13.49%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
LIMN Yearly ROA, ROE, ROICLIMN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 200 400 600

1.3 Margins

LIMN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LIMN Yearly Profit, Operating, Gross MarginsLIMN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023

0

2. Health

2.1 Basic Checks

The number of shares outstanding for LIMN has been reduced compared to 1 year ago.
LIMN has a worse debt/assets ratio than last year.
LIMN Yearly Shares OutstandingLIMN Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 10M 20M 30M
LIMN Yearly Total Debt VS Total AssetsLIMN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

LIMN has an Altman-Z score of -7.67. This is a bad value and indicates that LIMN is not financially healthy and even has some risk of bankruptcy.
LIMN has a worse Altman-Z score (-7.67) than 68.54% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -7.67
ROIC/WACCN/A
WACCN/A
LIMN Yearly LT Debt VS Equity VS FCFLIMN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 50M 100M 150M 200M 250M

2.3 Liquidity

A Current Ratio of 0.05 indicates that LIMN may have some problems paying its short term obligations.
LIMN has a Current ratio of 0.05. This is amonst the worse of the industry: LIMN underperforms 97.83% of its industry peers.
A Quick Ratio of 0.05 indicates that LIMN may have some problems paying its short term obligations.
LIMN has a Quick ratio of 0.05. This is amonst the worse of the industry: LIMN underperforms 97.83% of its industry peers.
Industry RankSector Rank
Current Ratio 0.05
Quick Ratio 0.05
LIMN Yearly Current Assets VS Current LiabilitesLIMN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 1M 2M 3M 4M 5M

0

3. Growth

3.1 Past

LIMN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -288.31%.
EPS 1Y (TTM)-288.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-125.13%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LIMN. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LIMN Price Earnings VS Forward Price EarningsLIMN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LIMN Per share dataLIMN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.1 -0.2 -0.3 -0.4 -0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

No dividends for LIMN!.
Industry RankSector Rank
Dividend Yield N/A

LIMINATUS PHARMA INC-CL A

NASDAQ:LIMN (7/29/2025, 8:00:02 PM)

Premarket: 6.9 +0.21 (+3.14%)

6.69

-1.39 (-17.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner Change0%
Market Cap174.01M
AnalystsN/A
Price TargetN/A
Short Float %4.49%
Short Ratio0.3
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.35
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.11
OCFYN/A
SpS0
BVpS-0.55
TBVpS-0.55
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -82.22%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)13.49%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.05
Quick Ratio 0.05
Altman-Z -7.67
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-288.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-125.13%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-126.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-126.78%
OCF growth 3YN/A
OCF growth 5YN/A